Literature DB >> 1634806

Blood-brain barrier damage in patients with bacterial meningitis: association with tumor necrosis factor-alpha but not interleukin-1 beta.

M K Sharief1, M Ciardi, E J Thompson.   

Abstract

Brain damage after meningeal infection could result from impairment of cerebral endothelial cell functions and disruption of blood-brain barriers. Tumor necrosis factor-alpha (TNF alpha) and interleukin-1 beta (IL-1 beta) produce many of their effects by acting on endothelial cells. This study correlates levels of TNF alpha and IL-1 beta in paired cerebrospinal fluid (CSF) and serum samples with the degree of blood-brain barrier damage, as manifested by CSF to serum albumin quotient, in 48 patients with bacterial meningitis and 66 controls. CSF levels of TNF alpha and IL-1 beta in bacterial meningitis were significantly higher than in controls. Intrathecal levels of TNF alpha, but not IL-1 beta, correlated with albumin quotient (P less than .001), with degree of blood-brain barrier disruption (P less than .001), and with disease severity and indices of meningeal inflammation. Sequential CSF samples demonstrated that IL-1 beta and TNF alpha disappear from the CSF within 24 h of antibiotic treatment. Data presented here suggest that TNF alpha is related to blood-brain barrier damage in bacterial meningitis and that its effect could be dissociated from that of IL-1 beta.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1634806     DOI: 10.1093/infdis/166.2.350

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  41 in total

Review 1.  Tuberculous meningitis.

Authors:  G Thwaites; T T Chau; N T Mai; F Drobniewski; K McAdam; J Farrar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-03       Impact factor: 10.154

2.  Effects of polysaccharide fucoidin on cerebrospinal fluid interleukin-1 and tumor necrosis factor alpha in pneumococcal meningitis in the rabbit.

Authors:  C Granert; J Raud; A Waage; L Lindquist
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

Review 3.  Concepts and mechanisms: crossing host barriers.

Authors:  Kelly S Doran; Anirban Banerjee; Olivier Disson; Marc Lecuit
Journal:  Cold Spring Harb Perspect Med       Date:  2013-07-01       Impact factor: 6.915

4.  Systemic inflammation alters the inflammatory response in experimental lipopolysaccharide-induced meningitis.

Authors:  T O'Reilly; C Ostergaard; J Vaxelaire; O Zak
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

Review 5.  Roles of proinflammatory and anti-inflammatory cytokines in pathophysiology of bacterial meningitis and effect of adjunctive therapy.

Authors:  A M van Furth; J J Roord; R van Furth
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

Review 6.  Pathogenesis and pathophysiology of pneumococcal meningitis.

Authors:  Barry B Mook-Kanamori; Madelijn Geldhoff; Tom van der Poll; Diederik van de Beek
Journal:  Clin Microbiol Rev       Date:  2011-07       Impact factor: 26.132

7.  Dexamethasone as an adjunctive treatment of bacterial meningitis.

Authors:  N M Shembesh; S M Elbargathy; I M Kashbur; B N Rao; K S Mahmoud
Journal:  Indian J Pediatr       Date:  1997 Jul-Aug       Impact factor: 1.967

Review 8.  Update on meningococcal disease with emphasis on pathogenesis and clinical management.

Authors:  M van Deuren; P Brandtzaeg; J W van der Meer
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

9.  Blood-brain barrier changes following intracerebral injection of human recombinant tumor necrosis factor-alpha in the rat.

Authors:  J L Wright; R E Merchant
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

10.  Phosphatidylcholine-specific phospholipase C from Listeria monocytogenes is an important virulence factor in murine cerebral listeriosis.

Authors:  D Schlüter; E Domann; C Buck; T Hain; H Hof; T Chakraborty; M Deckert-Schlüter
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.